Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.82T2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥3.56T2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.78T2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥27.2bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥35.1bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥64.6bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥29.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥39.8bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥32.8bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥21.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥41.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥17.2bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥27.6bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥22.5bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.88Tat 2024-09-30Cons.Assets
Total assets¥1.80Tat 2024-03-31Cons.Assets
Total assets¥1.82Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.12Tat 2024-09-30Cons.Liabilities
Total liabilities¥1.06Tat 2024-03-31Cons.Liabilities
Net assets / equity¥757.7bnat 2024-09-30Cons.Net assets
Net assets / equity¥736.6bnat 2024-03-31Cons.Net assets
Net assets / equity¥714.6bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥251.1bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥230.2bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥249.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥228.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥207.0bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥193.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥41.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥61.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥31.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥10.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥14.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥25.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥12.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥103.942024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥195.832023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥80.482023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio32.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.4%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30¥161m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥600.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥600.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥201m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥11.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥1.83T
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥1.82T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥27.0bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥37m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥583.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥583.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥146m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Impairment loss elCurrentYTDDuration168000000JPY
Other elPrior1YTDDuration26000000JPY
Other elCurrentYTDDuration93000000JPY
Extraordinary lossPrior1YTDDuration105000000JPY
Extraordinary lossCurrentYTDDuration290000000JPY
Income before income taxesPrior1YTDDuration32840000000JPY
Income before income taxesCurrentYTDDuration39774000000JPY
Income taxes currentPrior1YTDDuration16677000000JPY
Income taxes currentCurrentYTDDuration19982000000JPY
Income taxes deferredPrior1YTDDuration-6370000000JPY
Income taxes deferredCurrentYTDDuration-7777000000JPY
Income taxesPrior1YTDDuration10306000000JPY
Income taxesCurrentYTDDuration12204000000JPY
Profit lossPrior1YTDDuration22533000000JPY
Profit lossCurrentYTDDuration27569000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration5379000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration5842000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration17154000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration21727000000JPY
Profit lossPrior1YTDDuration22533000000JPY
Profit lossCurrentYTDDuration27569000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration7205000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration6165000000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration209000000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-55000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration108000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-156000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration826000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration1748000000JPY
Other comprehensive incomePrior1YTDDuration8349000000JPY
Other comprehensive incomeCurrentYTDDuration7701000000JPY
Comprehensive incomePrior1YTDDuration30883000000JPY
Comprehensive incomeCurrentYTDDuration35271000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration24636000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration29333000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration6246000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration5938000000JPY
Income before income taxesPrior1YTDDuration32840000000JPY
Income before income taxesCurrentYTDDuration39774000000JPY
Depreciation and amortization ope cfPrior1YTDDuration8221000000JPY
Depreciation and amortization ope cfCurrentYTDDuration8508000000JPY
Amortization of goodwill ope cfPrior1YTDDuration526000000JPY
Amortization of goodwill ope cfCurrentYTDDuration638000000JPY
Increase decrease in provision for bonuses ope cfPrior1YTDDuration-481000000JPY
Increase decrease in provision for bonuses ope cfCurrentYTDDuration-677000000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration-56000000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-61000000JPY
Increase decrease in provision for loss on disaster ope cfPrior1YTDDuration-JPY
Increase decrease in provision for loss on disaster ope cfCurrentYTDDuration-403000000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration-29000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass